PHIBRO ANIMAL HEALTH CORP

For the period ended Dec 31, 2024. Filed Feb 5, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Dec 31, 2024 · Filed Feb 5, 2025

PAHC$34.64+0.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Cash Flows


· · Six Months ·
For the Periods Ended December 31 · 2024 · 2023 ·
· · (unaudited) ·
· · (in thousands) ·
OPERATING ACTIVITIES · · ·
Net income (loss)	$10,160	$(6,741)
Adjustments to reconcile net income (loss) to
net cash provided by operating activities:
Depreciation and amortization	20,578	17,781
Amortization of debt issuance costs	871	520
Deferred income taxes	(12,623)	(6,506)
Foreign currency losses, net	11,350	2,355
Acquisition-related items	1,634	310
Pension settlement cost	—	10,674
Brazil employment taxes	—	4,202
Stock-based compensation expense	359	161
Other	(895)	2,513
Changes in operating assets and liabilities
Accounts receivable, net	(25,781)	14,316
Inventories, net	(24,401)	(7,546)
Other current assets	(5,737)	1,934
Other assets	4,330	(134)
Accounts payable	14,611	11,543
Accrued expenses and other liabilities	21,242	2,375
Net cash provided by operating activities	15,698	47,757
INVESTING ACTIVITIES
Purchases of short-term investments	—	(59,523)
Maturities of short-term investments	44,000	40,000
Capital expenditures	(17,405)	(18,435)
Business acquisition, net of cash acquired	(290,825)	(3,326)
Other, net	827	1,071
Net cash used by investing activities	(263,403)	(40,213)
FINANCING ACTIVITIES
Revolving credit facility borrowings	398,000	93,000
Revolving credit facility repayments	(460,000)	(83,000)
Proceeds from long-term debt	650,000	—
Payments of long-term debt	(316,890)	(10,210)
Debt issuance costs	(10,377)	—
Payments of insurance premium financing	(3,890)	(3,478)
Dividends paid	(9,720)	(9,721)
Net cash provided (used) by financing activities	247,123	(13,409)
Effect of exchange rate changes on cash	(2,957)	(2,446)
Net decrease in cash and cash equivalents	(3,539)	(8,311)
Cash and cash equivalents at beginning of period	70,613	41,281
Cash and cash equivalents at end of period	$67,074	$32,970

PHIBRO ANIMAL HEALTH CORPORATION AND SUBSIDIARIES

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.